Eurofins BioPharma Product Testing (BPT) has long history in small and large molecule biopharmaceutical testing and they are leveraging that experience to address the needs that are emerging in the cell and gene therapy industry. In this Q&A, learn how Eurofins BPT is not only integrating next-gen sequencing (NGS) into its cell and gene therapy workflows, but also how that technology is enhancing the accuracy and efficiency of its testing services, the ways Eurofins ensures compliance with regulatory standards, how it maintains data security and integrity in its NGS and other testing services, and more. Watch now to learn more.